Evidence map›Paper›PMID 35486307›Full record

ArticleJournal of neuro-oncology2022

Cognitive function after concurrent temozolomide-based chemoradiation therapy in low-grade gliomas.

Deborah Y Park, Martin C Tom, Yanwen Chen, Surabhi Tewari, Manmeet S Ahluwalia, Jennifer S Yu, Samuel T Chao, John H Suh, David M Peereboom, Glen H J Stevens and 10 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Multidisciplinary Management of Isocitrate Dehydrogenase-Mutated Gliomas in a Contemporary Molecularly Defined Era.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 1 country.

Deborah Y ParkCleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic, Cleveland, OH, USA.
Martin C TomDepartment of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA.
Yanwen ChenDepartment of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, 9500 Euclid Avenue/CA-60, Cleveland, OH, 44195, USA.
Surabhi TewariCleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic, Cleveland, OH, USA.
Manmeet S AhluwaliaDepartment of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA.
Jennifer S YuCleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic, Cleveland, OH, USA.
Samuel T ChaoCleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic, Cleveland, OH, USA.
John H SuhCleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic, Cleveland, OH, USA.
David M PeereboomCleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic, Cleveland, OH, USA.
Glen H J StevensCleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic, Cleveland, OH, USA.
Gene H BarnettCleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic, Cleveland, OH, USA.
Lilyana AngelovRose Ella Burkhardt Brain Tumor and Neuro-Oncology Center and Neurological Institute, Cleveland Clinic, Cleveland, USA.
Alireza MohammadiRose Ella Burkhardt Brain Tumor and Neuro-Oncology Center and Neurological Institute, Cleveland Clinic, Cleveland, USA.
Thomas HoganDepartment of Neuropsychology, Cleveland Clinic, Cleveland, OH, USA.
Courtney KisselDepartment of Neuropsychology, Cleveland Clinic, Cleveland, OH, USA.
Brittany LapinDepartment of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, 9500 Euclid Avenue/CA-60, Cleveland, OH, 44195, USA.
Isabel SchuermeyerDepartment of Psychiatry, Louis Stokes Cleveland VA Medical Center, Cleveland, OH, USA.
Michael W ParsonsNeuro-Oncology Center and Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA.
Richard NaugleCleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic, Cleveland, OH, USA.
Erin S MurphyCleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic, Cleveland, OH, USA. murphye3@ccf.org.
Cleveland Clinic · USCleveland Clinic Lerner College of Medicine · USCase Western Reserve University · USBaptist Health South Florida · USLouis Stokes Cleveland VA Medical Center · USMassachusetts General Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWe sought to evaluate the effects of concurrent temozolomide-based chemoradiation therapy on neurocognitive function in patients with low-grade glioma (LGG). MATERIALS/

methodsWe included adult patients with LGG who were treated postoperatively with radiotherapy (RT) with concurrent and adjuvant temozolomide (TMZ). Patients were evaluated with comprehensive psychometric tests at baseline (prior to RT + TMZ) and at various time intervals following RT + TMZ. Baseline cognitive performance was analyzed by sex, age, education history, history of seizures, IDH mutation status, and 1p/19q codeletion status. Changes in neurocognitive performance were evaluated over time.

resultsThirty-seven LGG patients (mean age 43.6, 59.5% male) had baseline neurocognitive evaluation. Patients with an age > 40 years old at diagnosis and those with an education > 16 years demonstrated superior baseline verbal memory as assessed by HVLT. No other cognitive domains showed differences when stratified by the variables mentioned above. A total of 22 LGG patients had baseline and post RT + TMZ neurocognitive evaluation. Overall, patients showed no statistical difference between group mean test scores prior to and following RT + TMZ on all psychometric measures (with the exception of HVLT Discrimination).

conclusionCognitive function remained stable following RT + TMZ in LGG patients evaluated prospectively up to 2 years. The anticipated analysis of RTOG 0424 will provide valuable neurocognitive outcomes specifically for high risk LGG patients treated with RT + TMZ.

Indexed as

Brain NeoplasmsGliomaAdultAntineoplastic Agents, AlkylatingCognitionFemaleHumansMaleTemozolomideAntineoplastic Agents, AlkylatingTemozolomideChemoradiationCognitive functionLow grade gliomaNeurocognitive testingTemozolomide

Identifiers

PMID35486307
OpenAlexW4225117539

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.